Treatment during a vulnerable developmental period rescues a genetic epilepsy
Marguet SL, Le-Schulte VT, Merseburg A, Neu A, Eichler R, Jakovcevski I, Ivanov A, Hanganu-Opatz IL, Bernard C, Morellini F, Isbrandt D.
Contributed by Sloka Iyengar
Nature Medicine, vol 21 no. 12, pp 1436-1444 December 2015 doi:10.1038/nm.3987
There is a greater incidence of epilepsy during the first few years of life as neurodevelopmental processes are still underway. The current strategy is to administer anti-epileptic drugs after seizures occur. The authors of a recent paper investigated whether administration of bumetanide – a diuretic that blocks the NKCC1 cation-chloride co-transporter and dampens down depolarization – would be effective as an anti-epileptogenic agent in a mouse model of mutated Kv7 K+ channels. Transient administration of bumetanide was able to correct structural and functional changes in the hippocampus in the mutant mice. This study raises the possibility of bumetanide as an anti-epileptogenic agent.
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community